P-286 Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3

Leleu, X., Bahlis, N., Rodriguez-Otero, P., Quach, H., Touzeau, C., Depaus, J., Iida, S., Hänel, M., Wrobel, T., Leip, E., Conte, U., Sullivan, S., Viqueira, A., & Lesokhin, A. (2023). P-286 Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3. Clinical Lymphoma Myeloma and Leukemia, 23, S194. https://doi.org/10.1016/s2152-2650(23)01904-3 (Original work published 2023)